<DOC>
	<DOCNO>NCT00976118</DOCNO>
	<brief_summary>This phase 2 study design evaluate activity oral masitinib ( AB1010 ) administer 2 dose level 24 week patient mild moderate confirm Alzheimer 's type disease .</brief_summary>
	<brief_title>Activity Masitinib ( AB1010 ) Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Outpatients sex 2 . Age ≥ 50 year screen 3 . Menopause ≥ 2 year woman 4 . Dementia Alzheimer 's type , accord DSM IV criteria 5 . Probable Alzheimer ' disease accord NINCDSADRDA criterion 6 . MMSE ≥ 12 ≤ 26 baseline 7 . CDR 1 2 baseline 8 . Treated minimum 6 month stable dose cholinesterase inhibitor ( donepezil , rivastigmine galantamine ) baseline , and/or stable dose memantine minimum 3 month baseline , change foresee therapy throughout study 9 . Presence reliable caregiver 10 . Patient , identify caregiver , applicable , patient surrogate able willing comply study visit procedure per protocol , understand , sign , date write voluntary informed consent form screen visit prior protocolspecific procedure perform 11 . Affiliated French Social Security regimen 1 . Any cause dementia due Alzheimer 's disease : central nervous condition cause progressive deficit memory cognition , e.g . cerebrovascular disease , Parkinson 's disease , Huntington 's disease , brain tumor… systemic condition know cause dementia , e.g. , hypothyroidism , untreated vitamin B12 folic acid deficiency , niacin deficiency , neurosyphilis , HIV infection… substanceinduced condition 2 . Alzheimer disease delusion delirium 3 . Treatment register putative cognitive enhancer disease modifier donepezil , galantamine , rivastigmine memantine 4 . Uncontrolled depression screen 5 . Evidence psychosis and/or use antipsychotic drug screen , history significant psychotic disorder hospitalization psychiatric disorder 6 . Active current bacterial , viral ( include hepatitis B C , HIV , EBV , CMV , herpes zoster , herpes simplex ) , fungal , mycobacterium , protozoan , infection . 7 . History infection require hospitalization treatment antibiotic within 2 week screen 8 . Inadequate organ function , define follow : total bilirubin ≥ 1.5 x ULN , SGOT SGPT ≥ 2.5 x UNL , creatinine clearance calculate Crocroft method &lt; 35 ml/mn , ANC ≤ 2500 , platelets ≤ 100 000 baseline 9 . Treatment investigational agent within 4 week screen , 10 . Men partner refuse use 2 method medically acceptable form contraception study . 11 . History poor compliance history drug/alcohol abuse , excessive alcohol beverage consumption would interfere ability comply study protocol , current past psychiatric disease might interfere ability comply study protocol give informed consent 12 . Any condition , investigator 's opinion , could detrimental subject participate study life expectancy &lt; 1 year , clinically important deviation normal clinical laboratory value concurrent medical event .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Dementia Alzheimer 's type</keyword>
	<keyword>mild moderate Alzheimer 's Disease</keyword>
</DOC>